{"id":28256,"date":"2022-07-07T22:44:00","date_gmt":"2022-07-07T14:44:00","guid":{"rendered":"https:\/\/flcube.com\/?p=28256"},"modified":"2025-02-27T22:47:06","modified_gmt":"2025-02-27T14:47:06","slug":"adicon-holdings-and-guardant-health-partner-on-genomic-profiling-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=28256","title":{"rendered":"Adicon Holdings and Guardant Health Partner on Genomic Profiling in China"},"content":{"rendered":"\n<p>China-based Adicon Holdings Limited announced a strategic partnership with U.S. firm Guardant Health, Inc. (<a href=\"https:\/\/www.google.com\/finance\/quote\/GH:NASDAQ\">NASDAQ: GH<\/a>), a leading precision oncology company, to bring Guardant\u2019s comprehensive genomic profiling (CGP) tests to biopharmaceutical firms conducting clinical trials in China. The deal grants Adicon access to Guardant\u2019s liquid biopsy technology, including the Guardant360, GuardantOMNI, and Guardant360 TissueNext tests, as well as the Guardant Reveal blood-only test for residual disease monitoring.<\/p>\n\n\n\n<p><strong>Partnership Details<\/strong><br>Under the agreement, Guardant Health will license its industry-leading liquid biopsy platform to Adicon, enabling the Chinese lab network to offer CGP services for solid tumor patients. Adicon will also gain rights to Guardant Reveal, the first blood-based test for early-stage cancer recurrence monitoring. The partnership aims to accelerate drug development in China by providing biopharma companies with advanced genomic tools.<\/p>\n\n\n\n<p><strong>Company Backgrounds<\/strong><br>Founded in 2011, Guardant Health is a global precision oncology leader, leveraging proprietary tests and data analytics to combat cancer. Adicon, a third-party medical lab operator with 26 units in China, will integrate Guardant\u2019s tech into its network to support oncology trials.<\/p>\n\n\n\n<p><strong>Market Impact<\/strong><br>The collaboration positions Adicon as a key player in China\u2019s growing genomic testing market, while Guardant expands its international footprint. The deal underscores the rising demand for liquid biopsy solutions in Asia\u2019s clinical research landscape.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>China-based Adicon Holdings Limited announced a strategic partnership with U.S. firm Guardant Health, Inc. (NASDAQ:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1150,16,2862,2863,109],"class_list":["post-28256","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-adicon","tag-cancer","tag-guardant-health","tag-nasdaq-gh","tag-precision-medicine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Adicon Holdings and Guardant Health Partner on Genomic Profiling in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Adicon Holdings Limited announced a strategic partnership with U.S. firm Guardant Health, Inc. (NASDAQ: GH), a leading precision oncology company, to bring Guardant\u2019s comprehensive genomic profiling (CGP) tests to biopharmaceutical firms conducting clinical trials in China. The deal grants Adicon access to Guardant\u2019s liquid biopsy technology, including the Guardant360, GuardantOMNI, and Guardant360 TissueNext tests, as well as the Guardant Reveal blood-only test for residual disease monitoring.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=28256\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adicon Holdings and Guardant Health Partner on Genomic Profiling in China\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=28256\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-07-07T14:44:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-27T14:47:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28256#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28256\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Adicon Holdings and Guardant Health Partner on Genomic Profiling in China\",\"datePublished\":\"2022-07-07T14:44:00+00:00\",\"dateModified\":\"2025-02-27T14:47:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28256\"},\"wordCount\":230,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Adicon\",\"Cancer\",\"Guardant Health\",\"NASDAQ: GH\",\"Precision medicine\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=28256#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28256\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=28256\",\"name\":\"Adicon Holdings and Guardant Health Partner on Genomic Profiling in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-07-07T14:44:00+00:00\",\"dateModified\":\"2025-02-27T14:47:06+00:00\",\"description\":\"China-based Adicon Holdings Limited announced a strategic partnership with U.S. firm Guardant Health, Inc. (NASDAQ: GH), a leading precision oncology company, to bring Guardant\u2019s comprehensive genomic profiling (CGP) tests to biopharmaceutical firms conducting clinical trials in China. The deal grants Adicon access to Guardant\u2019s liquid biopsy technology, including the Guardant360, GuardantOMNI, and Guardant360 TissueNext tests, as well as the Guardant Reveal blood-only test for residual disease monitoring.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28256#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=28256\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=28256#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adicon Holdings and Guardant Health Partner on Genomic Profiling in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Adicon Holdings and Guardant Health Partner on Genomic Profiling in China - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Adicon Holdings Limited announced a strategic partnership with U.S. firm Guardant Health, Inc. (NASDAQ: GH), a leading precision oncology company, to bring Guardant\u2019s comprehensive genomic profiling (CGP) tests to biopharmaceutical firms conducting clinical trials in China. The deal grants Adicon access to Guardant\u2019s liquid biopsy technology, including the Guardant360, GuardantOMNI, and Guardant360 TissueNext tests, as well as the Guardant Reveal blood-only test for residual disease monitoring.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=28256","og_locale":"en_US","og_type":"article","og_title":"Adicon Holdings and Guardant Health Partner on Genomic Profiling in China","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=28256","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-07-07T14:44:00+00:00","article_modified_time":"2025-02-27T14:47:06+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=28256#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=28256"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Adicon Holdings and Guardant Health Partner on Genomic Profiling in China","datePublished":"2022-07-07T14:44:00+00:00","dateModified":"2025-02-27T14:47:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=28256"},"wordCount":230,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Adicon","Cancer","Guardant Health","NASDAQ: GH","Precision medicine"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=28256#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=28256","url":"https:\/\/flcube.com\/?p=28256","name":"Adicon Holdings and Guardant Health Partner on Genomic Profiling in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-07-07T14:44:00+00:00","dateModified":"2025-02-27T14:47:06+00:00","description":"China-based Adicon Holdings Limited announced a strategic partnership with U.S. firm Guardant Health, Inc. (NASDAQ: GH), a leading precision oncology company, to bring Guardant\u2019s comprehensive genomic profiling (CGP) tests to biopharmaceutical firms conducting clinical trials in China. The deal grants Adicon access to Guardant\u2019s liquid biopsy technology, including the Guardant360, GuardantOMNI, and Guardant360 TissueNext tests, as well as the Guardant Reveal blood-only test for residual disease monitoring.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=28256#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=28256"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=28256#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Adicon Holdings and Guardant Health Partner on Genomic Profiling in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=28256"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28256\/revisions"}],"predecessor-version":[{"id":28257,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/28256\/revisions\/28257"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=28256"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=28256"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=28256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}